Free immunoglobulin light chain: Its biology and implications in diseases

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 843-849

  Nakano, Takanari ^a   Matsui, Masanori ^a   Inoue, Ikuo ^a   Awata, Takuya ^a   Katayama, Shigehiro ^a   Murakoshi, Takayuki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antibody; Antigen binding; Autoimmune diseases; B cells; Inflammation

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; PRE B CELL RECEPTOR;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; BINDING AFFINITY; BIOLOGICAL ACTIVITY; DIABETES MELLITUS; GENE EXPRESSION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; ANTIGENS; DISEASE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS;

EID: 79955043453     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.03.007     Document Type: Review

References (117)

1. Pilstrom L. The mysterious immunoglobulin light chain. Dev Comp Immunol 2002, 26:207-215.
2. Maizels N. Immunoglobulin gene diversification. Annu Rev Genet 2005, 39:23-46.
3. Shapiro A.L., Scharff M.D., Maizel J.V., Uhr J.W. Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature 1966, 211:243-245.
4. Waldmann T.A., Strober W., Mogielnicki R.P. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 1972, 51:2162-2174.
5. Hopper J.E., Papagiannes E. Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. Cell Immunol 1986, 101:122-131.
6. Pilstrom L., Lundqvist M.L., Wermenstam N.E. The immunoglobulin light chain in poikilothermic vertebrates. Immunol Rev 1998, 166:123-132.
7. Bradwell A.R. Serum free light chain measurements move to center stage. Clin Chem 2005, 51:805-807.
8. Bradwell A.R., Carr-Smith H., Mead G.P., Drayson M. Serum free light chain immunoassays and their clinical application. Clin Appl Immunol Rev 2002, 3:17-33.
9. Corcoran A.E. Immunoglobulin locus silencing and allelic exclusion. Semin Immunol 2005, 17:141-154.
10. Louzoun Y., Friedman T., Luning Prak E., Litwin S., Weigert M. Analysis of B cell receptor production and rearrangement. Part I. Light chain rearrangement. Semin Immunol 2002, 14:169-190. [discussion 221-122].
11. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996, 381:751-758.
12. Melchers F. The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nat Rev Immunol 2005, 5:578-584.
13. Melchers F., ten Boekel E., Seidl T., et al. Repertoire selection by pre-B-cell receptors and B-cell receptors, and genetic control of B-cell development from immature to mature B cells. Immunol Rev 2000, 175:33-46.
14. Feige M.J., Groscurth S., Marcinowski M., et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell 2009, 34:569-579.
15. Fagioli C., Mezghrani A., Sitia R. Reduction of interchain disulfide bonds precedes the dislocation of Ig-mu chains from the endoplasmic reticulum to the cytosol for proteasomal degradation. J Biol Chem 2001, 276:40962-40967.
16. Askonas B.A., Williamson A.R. Biosynthesis of immunoglobulins on polyribosomes and assembly of the IgG molecule. Proc R Soc Lond B Biol Sci 1966, 166:232-243.
17. Hannam-Harris A.C., Smith J.L. Free immunoglobulin light chain synthesis by human foetal liver and cord blood lymphocytes. Immunology 1981, 43:417-423.
18. Osserman E.F., Graff A., Marshall M., Lawlor D., Graff S. Incorporation of N15-L-aspartic acid into the abnormal serum and urine proteins of multiple myeloma; studies of the inter-relationship of these proteins. J Clin Invest 1957, 36:352-360.
19. Askonas B.A., Williamson A.R. Biosynthesis of immunoglobulins. Free light chain as an intermediate in the assembly of gamma G-molecules. Nature 1966, 211:369-372.
20. Imai H. Heavy chain deposition disease: report of a case and review of the literature. Rinsho Byori 2001, 49:695-698.
21. Coffino P., Scharff M.D. Rate of somatic mutation in immunoglobulin production by mouse myeloma cells. Proc Natl Acad Sci USA 1971, 68:219-223.
22. Kohler G. Immunoglobulin chain loss in hybridoma lines. Proc Natl Acad Sci USA 1980, 77:2197-2199.
23. Nakano T., Miyazaki S., Shinoda Y., et al. Proposed reference material for human free immunoglobulin light chain measurement. J Immunoassay Immunochem 2006, 27:129-137.
24. Solomon A. Bence-Jones proteins and light chains of immunoglobulins (first of two parts). N Engl J Med 1976, 294:17-23.
25. Sølling K. Free light chains of immunoglobulins. Scand J Clin Lab Invest Suppl 1981, 157:1-83.
26. Mogensen C.E., Sølling Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977, 37:477-486.
27. Mead G.P., Carr-Smith H.D., Drayson M.T., Morgan G.J., Child J.A., Bradwell A.R. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004, 126:348-354.
28. Wochner R.D., Strober W., Waldmann T.A. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967, 126:207-221.
29. Solomon A., Waldmann T.A., Fahey J.L., McFarlane A.S. Metabolism of Bence Jones proteins. J Clin Invest 1964, 43:103-117.
30. Batuman V., Verroust P.J., Navar G.L., et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 1998, 275:F246-F254.
31. Klassen R.B., Allen P.L., Batuman V., Crenshaw K., Hammond T.G. Light chains are a ligand for megalin. J Appl Physiol 2005, 98:257-263.
32. Christensen E.I., Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Ren Physiol 2001, 280:F562-F573.
33. Franklin E.C. Physicochemical and immunologic studies of gamma globulins of normal human urine. J Clin Invest 1959, 38:2159-2167.
34. Stevenson G.T. Further studies of the gamma-related proteins of normal urine. J Clin Invest 1962, 41:1190-1198.
35. Nakano T., Miyazaki S., Takahashi H., et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006, 44:522-532.
36. Nakano T., Miyazaki S., Shinoda Y., et al. Proposed reference material for human free immunoglobulin light chain measurement. J Immunoassay Immunochem 2006, 27:129-137.
37. Nakano T., Nagata A. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. J Immunol Meth 2004, 293:183-189.
38. Nakano T., Nagata A. ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies. J Immunol Meth 2003, 275:9-17.
39. Torres M., Casadevall A. The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol 2008, 29:91-97.
40. Porter R.R., Weir R.C. Subunits of immunoglobulins and their relationship to antibody specificity. J Cell Physiol 1966, 67(Suppl 1):51-64.
41. Painter R.G., Sage H.J., Tanford C. Contributions of heavy and light chains of rabbit immunoglobulin G to antibody activity. II. Binding activities of reconstituted immunoglobulins. Biochemistry 1972, 11:1338-1345.
42. Polymenis M., Stollar B.D. Domain interactions and antigen binding of recombinant anti-Z-DNA antibody variable domains. The role of heavy and light chains measured by surface plasmon resonance. J Immunol 1995, 154:2198-2208.
43. Franek F., Nezlin R.S. Recovery of antibody combining activity by interaction of different peptide chains isolated from purified horse antitoxins. Folia Microbiol Praha 1963, 8:128-130.
44. Hamers-Casterman C., Atarhouch T., Muyldermans S., et al. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
45. Nguyen V.K., Hamers R., Wyns L., Muyldermans S. Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J 2000, 19:921-930.
46. Ward E.S., Gussow D., Griffiths A.D., Jones P.T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989, 341:544-546.
47. Shlomchik M.J., Aucoin A.H., Pisetsky D.S., Weigert M.G. Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc Natl Acad Sci USA 1987, 84:9150-9154.
48. Radic M.Z., Mackle J., Erikson J., Mol C., Anderson W.F., Weigert M. Residues that mediate DNA binding of autoimmune antibodies. J Immunol 1993, 150:4966-4977.
49. Jang Y.J., Sanford D., Chung H.Y., Baek S.Y., Stollar B.D. The structural basis for DNA binding by an anti-DNA autoantibody. Mol Immunol 1998, 35:1207-1217.
50. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
51. Aguilera I., Melero J., Nunez-Roldan A., Sanchez B. Molecular structure of eight human autoreactive monoclonal antibodies. Immunology 2001, 102:273-280.
52. Crouzier R., Martin T., Pasquali J.L. Heavy chain variable region, light chain variable region, and heavy chain CDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors. J Immunol 1995, 154:4526-4535.
53. Ichiyoshi Y., Casali P. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med 1994, 180:885-895.
54. Brady G.F., Congdon K.L., Clark A.G., et al. Kappa editing rescues autoreactive B cells destined for deletion in mice transgenic for a dual specific anti-laminin Ig. J Immunol 2004, 172:5313-5321.
55. Wardemann H., Hammersen J., Nussenzweig M.C. Human autoantibody silencing by immunoglobulin light chains. J Exp Med 2004, 200:191-199.
56. Theoharides T.C., Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann NY Acad Sci 2006, 1088:78-99.
57. Sampson H.A. Update on food allergy. J Allergy Clin Immunol 2004, 113:805-819. [quiz 820].
58. Kaplan A.P. A new mechanism for immunologic initiation of asthma. Proc Natl Acad Sci USA 2005, 102:1267-1268.
59. Redegeld F.A., van der Heijden M.W., Kool M., et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002, 8:694-701.
60. Ying W.Z., Sanders P.W. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001, 158:1859-1866.
61. Huang Z.Q., Sanders P.W. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997, 99:732-736.
62. Winter G., Milstein C. Man-made antibodies. Nature 1991, 349:293-299.
63. Groot Kormelink T., Thio M., Blokhuis B.R., Nijkamp F.P., Redegeld F.A. Atopic and non-atopic allergic disorders: current insights into the possible involvement of free immunoglobulin light chains. Clin Exp Allergy 2009, 39:33-42.
64. Powe DG, Groot Kormelink T, Sisson M, et al. Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. J Allergy Clin Immunol 2010;125:139-45.
65. Kraneveld A.D., Kool M., van Houwelingen A.H., et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci USA 2005, 102:1578-1583.
66. van der Heijden M., Kraneveld A., Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006, 533:319-326.
67. Little J.R., Eisen H.N. Specificity of the immune response to the 2,4-dinitrophenyl and 2,4,6-trinitrophenyl groups. Ligand binding and fluorescence properties of cross-reacting antibodies. J Exp Med 1969, 129:247-265.
68. Nakano T., Takahashi H., Miyazaki S., et al. Antigen-specific free immunoglobulin light-chain antibodies: could it be a new diagnostic marker for patients with allergy?. Clin Biochem 2006, 39:955-959.
69. Bryce P.J., Miller M.L., Miyajima I., Tsai M., Galli S.J., Oettgen H.C. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 2004, 20:381-392.
70. Haag-Weber M., Horl W.H. Dysfunction of polymorphonuclear leukocytes in uremia. Semin Nephrol 1996, 16:192-201.
71. Cohen G., Rudnicki M., Horl W.H. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int Suppl 2001, 78:S48-S52.
72. Sølling K. Light chain polymerism in normal individuals in patients with severe proteinuria and in normals with inhibited tubular protein reabsorption by lysine. Scand J Clin Lab Invest 1980, 40:129-134.
73. Wakasugi K., Sasaki M., Suzuki M., Azuma N., Nobuto T. Increased concentrations of free light chain lambda in sera from chronic hemodialysis patients. Biomater Artif Cells Immobil Biotechnol 1991, 19:97-109.
74. Cohen G., Haag-Weber M., Mai B., Deicher R., Horl W.H. Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 1995, 6:1592-1599.
75. Cohen G., Horl W.H. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. Semin Dial 2009, 22:369-372.
76. Jacobson D.R., Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol 1986, 13:282-290.
77. Hutchison C.A., Cook M., Heyne N., et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008, 9:55.
78. Hutchison C.A., Basnayake K., Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol 2009, 5:621-628.
79. Matsumori A., Shimada M., Jie X., Higuchi H., Groot Kormelink T., Redegeld F.A. Effects of free immunoglobulin light chains on viral myocarditis. Circ Res 2010, 106:1533-1540.
80. Jorgensen T., Bogen B., Hannestad K. T helper cells recognize an idiotope located on peptide 88-114/117 of the light chain variable domain of an isologous myeloma protein (315). J Exp Med 1983, 158:2183-2188.
81. McNamara M., Kohler H. Regulatory idiotopes. Induction of idiotype-recognizing helper T cells by free light and heavy chains. J Exp Med 1984, 159:623-628.
82. Wall J.S., Ayoub F.M., O'Shea P.S. A study of the interactions of an immunoglobulin light chain with artificial and B-lymphocyte membranes. Front Biosci 1996, 1:a46-a58.
83. Cohen G. Immunoglobulin light chains in uremia. Kidney Int Suppl 2003, S15-S18.
84. Zhu L., Herrera G.A., Murphy-Ullrich J.E., Huang Z.Q., Sanders P.W. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol 1995, 147:375-385.
85. Epstein W.V., Grausz H. Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus. Arthritis Rheum 1974, 17:129-142.
86. Ohtani S., Ohtani H. Clinical significance of free light chain in urine by latex agglutination immunoassay. Kitasato Med 1998, 28:435-445.
87. Hopper J.E., Sequeira W., Martellotto J., Papagiannes E., Perna L., Skosey J.L. Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin. J Clin Immunol 1989, 9:338-350.
88. Hopper J.E., Golbus J., Meyer C., Ferrer G.A. Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 2000, 20:123-137.
89. Epstein W.V., Tan M. Increase of L-chain proteins in the sera of patients with systemic lupus erythematosus and the synovial fluids of patients with peripheral rheumatoid arthritis. Arthritis Rheum 1966, 9:713-719.
90. Gottenberg J.E., Aucouturier F., Goetz J., et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007, 66:23-27.
91. Rudick R.A., Pallant A., Bidlack J.M., Herndon R.M. Free kappa light chains in multiple sclerosis spinal fluid. Ann Neurol 1986, 20:63-69.
92. DeCarli C., Menegus M.A., Rudick R.A. Free light chains in multiple sclerosis and infections of the CNS. Neurology 1987, 37:1334-1338.
93. Fagnart O.C., Sindic C.J., Laterre C. Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. J Neuroimmunol 1988, 19:119-132.
94. Rudick R.A., French C.A., Breton D., Williams G.W. Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests. Neurology 1989, 39:964-968.
95. Lolli F., Siracusa G., Amato M.P., et al. Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis. Acta Neurol Scand 1991, 83:239-243.
96. Mehta P.D., Cook S.D., Troiano R.A., Coyle P.K. Increased free light chains in the urine from patients with multiple sclerosis. Neurology 1991, 41:540-544.
97. Rudick R.A., Medendorp S.V., Namey M., Boyle S., Fischer J. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995, 1:150-155.
98. Rudick R.A., Jacobs L., Kinkel P.R., Kinkel W.R. Isolated idiopathic optic neuritis. Analysis of free kappa-light chains in cerebrospinal fluid and correlation with nuclear magnetic resonance findings. Arch Neurol 1986, 43:456-458.
99. Matsumori A., Horii T., Nakano T., Isomura T., Suma H. Increased serum concentrations of free immunoglobulin light-chains - a new clinical biomarker for the evaluation of heart failure 2005, American Heart Association Scientific Sessions, Dallas Texas, USA.
100. Palladini G., Lavatelli F., Russo P., et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006, 107:3854-3858.
101. Teppo A.M., Groop L. Urinary excretion of plasma proteins in diabetic subjects. Increased excretion of kappa light chains in diabetic patients with and without proliferative retinopathy. Diabetes 1985, 34:589-594.
102. Groop L., Makipernaa A., Stenman S., DeFronzo R.A., Teppo A.M. Urinary excretion of kappa light chains in patients with diabetes mellitus. Kidney Int 1990, 37:1120-1125.
103. Sølling K. Polymeric forms of free light chains in serum from normal individuals and from patients with renal diseases. Scand J Clin Lab Invest 1976, 36:447-452.
104. Abraham G.N., Waterhouse C. Evidence for defective immunoglobulin metabolism in severe renal insufficiency. Am J Med Sci 1974, 268:227-233.
105. Robinson E.L., Gowland E., Ward I.D., Scarffe J.H. Radioimmunoassay of free light chains of immunoglobulins in urine. Clin Chem 1982, 28:2254-2258.
106. Sølling K., Sølling J., Romer F.K. Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand 1981, 209:473-477.
107. Fischer C., Arneth B., Koehler J., Lotz J., Lackner K.J. Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. Clin Chem 2004, 50:1809-1813.
108. Elovaara I., Seppala I., Kinnunen E., Laaksovirta H. Increased occurrence of free immunoglobulin light chains in cerebrospinal fluid and serum in human immunodeficiency virus-1 infection. J Neuroimmunol 1991, 35:65-77.
109. Gallo P., Piccinno M.G., De Rossi A., et al. Free light chains of immunoglobulins in the cerebrospinal fluid of human immunodeficiency virus type 1-infected patients. J Neuroimmunol 1990, 26:229-238.
110. Thompson E.J. Quality versus quantity: which is better for cerebrospinal fluid IgG?. Clin Chem 2004, 50:1721-1722.
111. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
112. Hong C.Y., Chia K.S. Markers of diabetic nephropathy. J Diab Complications 1998, 12:43-60.
113. Coll A.P., Loraine Tung Y.C. Pro-opiomelanocortin (POMC)-derived peptides and the regulation of energy homeostasis. Mol Cell Endocrinol 2009, 300:147-151.
114. Drucker D.J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005, 1:22-31.
115. Hills C.E., Brunskill N.J. Cellular and physiological effects of C-peptide. Clin Sci Lond 2009, 116:565-574.
116. Elliott M.R., Chekeni F.B., Trampont P.C., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461:282-286.
117. Corriden R., Insel P.A. Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. Sci Signal 2010, 3. [re1].